[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
A new anticancer therapy using tegafur encapsulated in slow-releasing granules (SF-SP) was orally administered at a dose of 1000 mg/day to 38 patients with cancer of the digestive organs. Twenty-eight of these patients were evaluable for response using the criteria of Saito and Koyama's clinical evaluation. Six of 28 patients showed effective response (21.4%). An effective response was observed in of 15 patients with gastric cancer (26.7%). Side-effects from this therapy were encountered in 14 patients (36.8%). An effective response was therefore demonstrated in patients with cancer of the digestive organs.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002214:Capsules; D003110:Colonic Neoplasms / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
D002214:Capsules; D003692:Delayed-Action Preparations; D005641:Tegafur; D005472:Fluorouracil